Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)
Alexas_Fotos / Pixabay

Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)

According to a story from globenewswire.com, the biopharmaceutical company ContraVir Pharmaceuticals, Inc. has recently announced that its experimental drug CRV431 was able to successfully decrease scarring of the liver in…

Continue Reading Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)

Mouse Model Continues to Show Efficacy of GKT831 for Treating Cholestatic Fibrosis in Primary Biliary Cholangitis

Preclinical data supporting the efficacy of GKT831 as a potential therapy for cholestatic fibrosis has just been published in the Journal of Hepatology. GKT831 GKT831 is both a NOX1 enzyme and…

Continue Reading Mouse Model Continues to Show Efficacy of GKT831 for Treating Cholestatic Fibrosis in Primary Biliary Cholangitis

New Potential Primary Biliary Cholangitis Treatment Granted Breakthrough Therapy Designation

Researchers at GENFIT are excited about promising results from studies investigating a new potential therapy for PBC and NASH, two rare liver diseases. Primary Biliary Cholangitis Primary biliary cholangitis (PBC)…

Continue Reading New Potential Primary Biliary Cholangitis Treatment Granted Breakthrough Therapy Designation

The Struggles of being a Rare Disease Patient in China

The State of Rare Diseases in China The Illness Challenge Foundation (ICF) is an organization devoted to easing the burdens that rare disease patients living in China face. They accomplish this…

Continue Reading The Struggles of being a Rare Disease Patient in China

Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH), is condition most commonly caused by obesity or type 2 diabetes. It can result in fibrosis, complications in the lung and cardiac system, liver cancer, liver cirrhosis,…

Continue Reading Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis
Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU
Capri23auto / Pixabay

Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU

According to a story from Market Screener, the drug developer Albireo Pharma, Inc., recently announced that its investigational product candidate A4250 has earned Orphan Drug designation from the European Commission.…

Continue Reading Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU

A Study of a Potential Drug for Primary Biliary Cholangitis has Exceeded its Patient Enrolment Target

The company Genkyotex has announced that they have finished enrolling participants for a Phase 2 clinical trial of the investigational drug GKT831 in patients who have primary biliary cholangitis. The…

Continue Reading A Study of a Potential Drug for Primary Biliary Cholangitis has Exceeded its Patient Enrolment Target
Diagnosing Primary Biliary Cholangitis: What You Should Know
https://pixabay.com/en/medical-appointment-doctor-563427/

Diagnosing Primary Biliary Cholangitis: What You Should Know

Sometimes, the path to diagnosis takes many twists and turns. This is true for people who have Primary Biliary Cholangitis (PBC), according to Gail from the PBC Society of Canada. In this video, she…

Continue Reading Diagnosing Primary Biliary Cholangitis: What You Should Know